Bernard P. Murray

3.0k citations

61 papers · 2.0k indexed · 1 hit paper · h-index 24

Impact in

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
Virology top 2%
- HIV Research and Treatment

Papers in

Pharmacology 27
- Pharmacogenetics and Drug Metabolism 26
Virology 4

Co-authors: Alan R. Boobis Robert J. Edwards Donald S. Davies Julie A. Di Paolo Federico Campigotto Amy Meng René Galien Paqui G. Través
Journals: Drug Metabolism and Disposition (5 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Molecular Pharmacology (3 papers)Carcinogenesis (3 papers)Annals of the Rheumatic Diseases (3 papers)
Partner nations: United States United Kingdom China

In The Last Decade

Bernard P. Murray

60 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib 2021 · 218 citations

Peers

Countries citing papers authored by Bernard P. Murray

Since Specialization

Citations

This map shows the geographic impact of Bernard P. Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard P. Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard P. Murray more than expected).

Fields of papers citing papers by Bernard P. Murray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard P. Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard P. Murray. The network helps show where Bernard P. Murray may publish in the future.

Co-authors

The 25 scholars most cited alongside Bernard P. Murray, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bernard P. Murray Line = papers co-authored together Bernard P. Murray links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hydrogen/Deuterium Exchange for Chiral Stability Assessment in Acidic Methine-Containing Compounds Analytical Chemistry ·Vidal Graupera, Sergei P. Babailov, Thomas Paul, Enakshi Das, Xiaolin Zhang, Widyhastuti Widyhastuti, Chandrasekar Venkataramani, Anna Guaita Crespo, Murali Subramanian, Bernard P. Murray, Xingrong Liu, Raju Subramanian	2025	0
2	Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway Journal of Pharmacology and Experimental Therapeutics ·Jim Zheng, Bing Lu, Gavin Carr, Judy Mwangi, Kelly Wang, Duan Meitao, Farel Faleri, H.-G. Struve, Bernard P. Murray, Y U Bratishko, Mark Gohdes, Winston C. Tse, Scott D. Schroeder, Johan Hermelin, John O. Link, Raisa Ruslan, Anna Chiu, William Rowe, Bill J. Smith, Raju Subramanian	2024	6
3	Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs Drug Metabolism and Disposition ·Renmeng Liu, Bin Ma, А. Э. Свирид, Bernard P. Murray, Raju Subramanian, Yurong Lai	2023	3
4	Human and nonclinical disposition of [¹⁴C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection Xenobiotica ·Raju Subramanian, John Ling, Jianhong Wang, Kelly Wang, Oscar Chávez, Haolun Jin, Yurong Lai, Bernard P. Murray, Soo-jin Sohn, Heather Zhang, Bill J. Smith	2022	4
5	Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy^® for the treatment of HIV-1 infection Xenobiotica ·Raju Subramanian, Jianhong Wang, Bernard P. Murray, Joseph M. Custodio, Oscar Chávez, Scott E. Lazerwith, P. A. Lux, Judy Mwangi, Hailing Sun, Jennifer Tang, Kelly Wang, Gerry Rhodes, Soo-jin Sohn, Heather Zhang, Bill J. Smith	2022	3
6	Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species Drug Metabolism and Disposition ·Abdul Basit, Peter W. Fan, S. Cyrus Khojasteh, Bernard P. Murray, Bill J. Smith, Scott Heyward, Bhagwat Prasad	2021	23
7	Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis BMC Rheumatology ·Christopher W. Pohlmeyer, Ching Shang, Ed E. Hansbrough, Zhi-Hua Cui, Randall M. Jones, Astrid Clarke, Bernard P. Murray, David López, David W. Newstrom, 顾丽华, F. Matzkies, Kevin Currie, Julie A. Di Paolo	2021	10
8	Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat Kidney International ·Eve‐Irene Lepist, Xuexiang Zhang, Hao Jia, Y. Li, Alan Kosaka, Gabriel Birkuš, Bernard P. Murray, Roy Bannister, Tomáš Cihlář, Yong Huang, Adrian S. Ray	2014	190
9	Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity Clinical Pharmacology & Therapeutics ·Anita Mathias, Polina German, Bernard P. Murray, John Fortuna, Aakanksha Jain, Steve West, David R. Warren, James Hoi Po Hui, Brian P. Kearney	2009	171
10	PhRMA White Paper on ADME Pharmacogenomics The Journal of Clinical Pharmacology ·J. Andrew Williams, Tommy Andersson, Tommy B. Andersson, Rebecca Blanchard, Cheng Siyi, Nadine Cohen, Timi Edeki, 裕渡邊, Kathleen M. Hillgren, Keith Johnson, David A. Katz, Mark Milton, Bernard P. Murray, Joseph W. Polli, Velimir Mijatović, Lisa A. Shipley, Vangala Subrahmanyam, Steven Wrighton	2008	37
11	Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy Nature Reviews Drug Discovery ·David A. Katz, Bernard P. Murray, Anahita Bhathena, Evan A. N. Marks	2008	24
12	Native CYP2C11: Heterologous Expression in Saccharomyces cerevisiae Reveals a Role for Vacuolar Proteases Rather Than the Proteasome System in the Degradation of This Endoplasmic Reticulum Protein Molecular Pharmacology ·Bernard P. Murray, Victor G. Zgoda, Maria Almira Correia	2002	2
13	Structure–Function Relationships of Rat Hepatic Tryptophan 2,3-Dioxygenase: Identification of the Putative Heme-Ligating Histidine Residues Archives of Biochemistry and Biophysics ·Ryan A. Dick, Bernard P. Murray, Michael Reid, Maria Almira Correia	2001	22
14	Ubiquitin-Dependent 26S Proteasomal Pathway: A Role in the Degradation of Native Human Liver CYP3A4 Expressed in Saccharomyces Cerevisiae? Archives of Biochemistry and Biophysics ·Bernard P. Murray, Maria Almira Correia	2001	32
15	Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes Biochemical Pharmacology ·Robert J. Edwards, Mohammed Almahdi Balla Elnour, Bernard P. Murray, D. S. Davies, Alan R. Boobis	1995	46
16	Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP Carcinogenesis ·Bernard P. Murray, Robert J. Edwards, Stephen Murray, Mohammed Almahdi Balla Elnour, Donald S. Davies, Alan R. Boobis	1993	63
17	N-Hydroxy-MeIQx is the major microsomal oxidation product of the dietary carcinogen MeIQx with human liver Carcinogenesis ·Kim J. Rich, Bernard P. Murray, Ivor A. S. Lewis, Nigel B. Rendell, Donald S. Davies, Nigel J. Gooderham, Alan R. Boobis	1992	39
18	Identification of the epitope of a monoclonal antibody which binds to several cytochromes P450 in the CYP1A subfamily Biochemical Pharmacology ·Robert J. Edwards, Dorothea Sesardic, Bernard P. Murray, Mohammed Almahdi Balla Elnour, Donald S. Davies, Alan R. Boobis	1992	7
19	Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors Xenobiotica ·Alan R. Boobis, Dorothea Sesardic, Bernard P. Murray, Robert J. Edwards, V. Khodaparast, Kim J. Rich, Sandra Murray, Rafael de la Torre, Jordi Segura, Olavi Pelkonen, Markku Pasanen, Shinichi Kobayashi, Zhiguang Tu, D. S. Davies	1990	96
20	The Role of Cytochrome P-450 LM4 in the Activation of the Dietary Carcinogen MeIQx Human Toxicology ·Bernard P. Murray, Alan R. Boobis, Dorothea Sesardic, Robert J. Edwards, D. S. Davies	1988	2

About Bernard P. Murray

Bernard P. Murray is a scholar working on Pharmacology, Virology, Infectious Diseases, Oncology and Cancer Research, having authored 61 papers that have together received 2.0k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (26 papers), Drug Transport and Resistance Mechanisms (13 papers), HIV/AIDS drug development and treatment (11 papers), Carcinogens and Genotoxicity Assessment (7 papers), Pharmacological Effects and Toxicity Studies (6 papers), Endoplasmic Reticulum Stress and Disease (5 papers), Ubiquitin and proteasome pathways (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Pharmacology (761 citations), Virology (238 citations), Infectious Diseases (491 citations), Oncology (575 citations) and Emergency Medicine (122 citations). Bernard P. Murray has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Alan R. Boobis, Robert J. Edwards, Donald S. Davies, Julie A. Di Paolo, Federico Campigotto, Amy Meng, René Galien, Paqui G. Través, Robert J. Edwards and Adrian S. Ray. Their work appears in journals such as Drug Metabolism and Disposition, Bioorganic & Medicinal Chemistry Letters, Molecular Pharmacology, Carcinogenesis and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact